Halozyme Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 373
- Market Cap
- $8B
- Website
- http://www.halozyme.com
- Introduction
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and a...
US FDA approves injectable version of Roche's multiple sclerosis therapy
The FDA approved Roche's Ocrevus Zunovo, an under-the-skin injection for multiple sclerosis, expanding treatment options to centers unable to administer the IV version. The 10-minute injection, given twice a year, targets CD20-positive B cells and is based on a study showing no significant difference in Ocrevus levels when administered subcutaneously.
Roche's Tecentriq Hybreza Gets FDA Approval For Subcutaneous Use
Roche's Tecentriq Hybreza, using Halozyme's ENHANZE tech, received FDA approval for subcutaneous administration in 7 mins, vs. 30-60 mins IV infusion. Available for all adult IV Tecentriq indications, including lung, liver, skin, and soft tissue cancers. Combines atezolizumab with rHuPH20 enzyme.
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
The FDA approved Roche's subcutaneous formulation of Tecentriq, branded as Tecentriq Hybreza, making it the first SC anti-PD-(L)1 cancer immunotherapy in the U.S. The SC option reduces treatment time to about 7 minutes compared to 30-60 minutes for IV infusion and is available for all Tecentriq indications.
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ...
FDA approves Roche's OCREVUS ZUNOVO™ with Halozyme's ENHANZE® for RMS and PPMS, offering a 10-minute subcutaneous injection.
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™
Roche received FDA approval for OCREVUS ZUNOVO™, a subcutaneous injection using Halozyme's ENHANZE® technology for RMS and PPMS, offering a 10-minute, twice-a-year treatment.
FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute
FDA approves Ocrevus Zunovo™, a twice-a-year, 10-minute subcutaneous injection for relapsing and primary progressive multiple sclerosis, offering more treatment options based on individual needs.
FDA grants approval to Roche's Tecentriq Hybreza for cancer
FDA approves Roche’s subcutaneous Tecentriq Hybreza, offering quicker and more comfortable cancer immunotherapy. Administered in 7 minutes, it covers all Tecentriq IV indications, with comparable safety and efficacy. Patient preference for Hybreza is strong, citing reduced clinic time and increased comfort.
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE®
Halozyme announces FDA approval for Roche's Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using ENHANZE® technology, offering faster administration and broader treatment options for lung, liver, skin, and soft tissue cancers.
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for ...
FDA approves Roche's Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using Halozyme's ENHANZE® technology, reducing injection time to 7 minutes from 30-60 minutes for IV infusion, available for adult indications of IV Tecentriq® in the U.S.
© Copyright 2024. All Rights Reserved by MedPath